Spyre Therapeutics, Inc. (SYRE) 10-Year Financial Performance & Capital Metrics

SYRE • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutSpyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Show more

Revenue $0 -100.0%
EBITDA -$208M +13.8%
Net Income -$208M +38.6%
EPS (Diluted) -3.18 +93.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -59.28% +79.5%
ROIC -73.87% +96.9%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM83.73%

ROCE

10Y Avg-78.09%

5Y Avg-85.99%

3Y Avg-98.82%

Latest-48.26%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6.08M	4.63M	5.21M	3.89M	0	0	18.74M	2.33M	886K	0
Revenue Growth %	-	-0.24%	0.12%	-0.25%	-1%	-	-	-0.88%	-0.62%	-1%
Cost of Goods Sold+	0	0	0	0	901K	1.62M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	-901K	-1.62M	18.74M	2.33M	886K	0
Gross Margin %	-	-	-	-	-	-	1%	1%	1%	-
Gross Profit Growth %	1%	-	-	-	-	-0.8%	12.54%	-0.88%	-0.62%	-1%
Operating Expenses+	17.4M	26.53M	32.88M	49.35M	79.43M	79.86M	84.39M	87.11M	243.19M	208.57M
OpEx % of Revenue	2.86%	5.73%	6.32%	12.69%	-	-	4.5%	37.4%	274.48%	-
Selling, General & Admin	5.95M	8.39M	10.07M	12.63M	14.83M	20.22M	27.32M	28.53M	39.95M	45.78M
SG&A % of Revenue	0.98%	1.81%	1.93%	3.25%	-	-	1.46%	12.25%	45.09%	-
Research & Development	11.45M	18.14M	22.82M	36.72M	64.6M	59.64M	57.07M	58.58M	89.5M	162.79M
R&D % of Revenue	1.88%	3.92%	4.38%	9.44%	-	-	3.05%	25.15%	101.02%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	113.74M	0
Operating Income+	-11.31M	-21.91M	-27.68M	-45.46M	-80.33M	-81.48M	-65.65M	-84.78M	-242.3M	-208.57M
Operating Margin %	-1.86%	-4.73%	-5.32%	-11.69%	-	-	-3.5%	-36.4%	-273.48%	-
Operating Income Growth %	-0.27%	-0.94%	-0.26%	-0.64%	-0.77%	-0.01%	0.19%	-0.29%	-1.86%	0.14%
EBITDA+	-11.23M	-21.77M	-27.43M	-45.17M	-79.43M	-79.86M	-64.07M	-82.82M	-241.34M	-207.97M
EBITDA Margin %	-1.84%	-4.7%	-5.27%	-11.62%	-	-	-3.42%	-35.56%	-272.39%	-
EBITDA Growth %	-0.26%	-0.94%	-0.26%	-0.65%	-0.76%	-0.01%	0.2%	-0.29%	-1.91%	0.14%
D&A (Non-Cash Add-back)	89K	132K	249K	293K	901K	1.62M	1.58M	1.96M	964K	0
EBIT	-11.31M	-21.91M	-27.68M	-45.46M	-78.25M	-80.89M	-65.65M	-84.78M	-128.56M	-207.97M
Net Interest Income+	22K	244K	482K	1.17M	2.14M	593K	111K	837K	6.15M	21.31M
Interest Income	22K	244K	482K	1.17M	2.14M	593K	111K	837K	6.15M	21.31M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	20K	208K	440K	1.11M	2.08M	588K	-11K	830K	-96.51M	599K
Pretax Income+	-11.29M	-21.7M	-27.24M	-44.35M	-78.25M	-80.89M	-65.66M	-83.95M	-338.82M	-207.97M
Pretax Margin %	-1.86%	-4.69%	-5.23%	-11.41%	-	-	-3.5%	-36.05%	-382.41%	-
Income Tax+	0	0	0	0	0	0	141K	-136K	-26K	51K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-11.29M	-21.7M	-27.24M	-44.35M	-78.25M	-80.89M	-65.8M	-83.81M	-338.79M	-208.02M
Net Margin %	-1.86%	-4.69%	-5.23%	-11.41%	-	-	-3.51%	-35.99%	-382.38%	-
Net Income Growth %	-0.09%	-0.92%	-0.26%	-0.63%	-0.76%	-0.03%	0.19%	-0.27%	-3.04%	0.39%
Net Income (Continuing)	-11.29M	-21.7M	-27.24M	-44.35M	-78.25M	-80.89M	-65.8M	-83.81M	-338.79M	-208.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-24.71	-55.40	-45.01	-53.25	-61.23	-37.89	-25.02	-24.86	-46.15	-3.18
EPS Growth %	-0.31%	-1.24%	0.19%	-0.18%	-0.15%	0.38%	0.34%	0.01%	-0.86%	0.93%
EPS (Basic)	-24.71	-55.40	-45.01	-53.25	-61.23	-37.89	-25.02	-24.86	-46.15	-3.18
Diluted Shares Outstanding	457.19K	391.67K	605.13K	832.9K	1.28M	2.13M	2.63M	3.37M	6.9M	47.03M
Basic Shares Outstanding	457.19K	391.67K	605.13K	832.9K	1.28M	2.13M	2.63M	3.37M	6.9M	47.03M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	38.29M	66.42M	54.99M	76.67M	74.5M	149.79M	98.89M	62.26M	341.53M	608.47M
Cash & Short-Term Investments	33.06M	63.5M	50.3M	74.51M	71.95M	146.27M	93.13M	55.71M	339.28M	603.09M
Cash Only	29.29M	47.75M	12.82M	22.46M	19.25M	90.09M	15.14M	34.86M	188.89M	89.42M
Short-Term Investments	3.77M	15.75M	37.48M	52.05M	52.7M	56.18M	77.99M	20.85M	150.38M	513.66M
Accounts Receivable	1.7M	1.22M	3.08M	0	0	0	815K	375K	0	0
Days Sales Outstanding	101.79	95.82	215.84	-	-	-	15.87	58.77	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2.62M	0	0	0	0	0	0	6.17M	2.25M	5.39M
Total Non-Current Assets+	368K	639K	1.09M	1.07M	8.68M	11.83M	11.04M	8.89M	331K	10K
Property, Plant & Equipment	348K	599K	854K	1.02M	7.11M	9.87M	8.36M	6.65M	0	0
Fixed Asset Turnover	17.49x	7.73x	6.09x	3.82x	-	-	2.24x	0.35x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	20K	40K	232K	50K	1.57M	1.96M	2.68M	2.24M	331K	10K
Total Assets+	38.65M	67.06M	56.08M	77.74M	83.18M	161.62M	109.93M	71.14M	341.86M	608.48M
Asset Turnover	0.16x	0.07x	0.09x	0.05x	-	-	0.17x	0.03x	0.00x	-
Asset Growth %	12.19%	0.73%	-0.16%	0.39%	0.07%	0.94%	-0.32%	-0.35%	3.81%	0.78%
Total Current Liabilities+	2.52M	3.96M	5.63M	10.24M	18.36M	16.44M	20.14M	14.66M	31.98M	54.06M
Accounts Payable	176K	168K	389K	663K	3.15M	2.25M	3.32M	677K	896K	666K
Days Payables Outstanding	-	-	-	-	1.28K	506.59	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	71K	20K	0	0	0	1000K	517K	0	0
Other Current Liabilities	621K	1.5M	3.38M	2.78M	3.74M	4.18M	4.99M	4.92M	5.93M	52.79M
Current Ratio	15.17x	16.75x	9.77x	7.49x	4.06x	9.11x	4.91x	4.25x	10.68x	11.26x
Quick Ratio	15.17x	16.75x	9.77x	7.49x	4.06x	9.11x	4.91x	4.25x	10.68x	11.26x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	27K	132K	111K	72K	4.74M	5.34M	5.84M	6.18M	125.86M	36.62M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	4.71M	5.13M	4.62M	4M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	27K	132K	111K	72K	31K	214K	0	0	125.86M	36.62M
Total Liabilities	2.55M	4.1M	5.74M	10.31M	23.1M	21.79M	25.98M	20.84M	157.84M	90.68M
Total Debt+	0	0	0	0	5.06M	5.45M	5.06M	4.63M	0	0
Net Debt	-29.29M	-47.75M	-12.82M	-22.46M	-14.19M	-84.65M	-10.08M	-30.23M	-188.89M	-89.42M
Debt / Equity	-	-	-	-	0.08x	0.04x	0.06x	0.09x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	36.1M	62.97M	50.34M	67.43M	60.08M	139.83M	83.94M	50.3M	184.02M	517.8M
Equity Growth %	18.29%	0.74%	-0.2%	0.34%	-0.11%	1.33%	-0.4%	-0.4%	2.66%	1.81%
Book Value per Share	78.97	160.76	83.18	80.96	47.01	65.50	31.92	14.92	26.68	11.01
Total Shareholders' Equity	36.1M	62.97M	50.34M	67.43M	60.08M	139.83M	83.94M	50.3M	184.02M	517.8M
Common Stock	0	1K	2K	2K	3K	5K	5K	6K	10K	13K
Retained Earnings	-23.58M	-45.28M	-72.51M	-116.86M	-195.12M	-276.01M	-341.81M	-425.62M	-764.41M	-972.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1K	-4K	-102K	-27K	51K	11K	-20K	-48K	302K	180K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.98M	-18.84M	-24.61M	-32.19M	-65.69M	-75.78M	-53.72M	-80.14M	-99.91M	-157.41M
Operating CF Margin %	-1.8%	-4.07%	-4.73%	-8.28%	-	-	-2.87%	-34.41%	-112.77%	-
Operating CF Growth %	-0.5%	-0.72%	-0.31%	-0.31%	-1.04%	-0.15%	0.29%	-0.49%	-0.25%	-0.58%
Net Income	-11.29M	-21.7M	-27.24M	-44.35M	-78.25M	-80.89M	-65.8M	-83.81M	-338.79M	-208.02M
Depreciation & Amortization	89K	132K	249K	293K	901K	996K	1.58M	1.57M	744K	0
Stock-Based Compensation	767K	0	0	0	0	6.26M	8.04M	7.11M	25.68M	44.83M
Deferred Taxes	0	0	0	0	0	-213K	0	-327K	0	0
Other Non-Cash Items	790K	1.07M	4.77M	1.93M	3.78M	619K	638K	823K	217.67M	10.31M
Working Capital Changes	-1.33M	1.45M	-198K	7.2M	7.1M	-2.54M	1.83M	-5.5M	-5.21M	-4.53M
Change in Receivables	-1.7M	482K	-1.86M	3.08M	0	0	-815K	440K	375K	0
Change in Inventory	0	0	0	0	0	0	0	-440K	0	0
Change in Payables	-169K	-8K	164K	239K	2.58M	-544K	1.06M	-2.64M	218K	-230K
Cash from Investing+	-4.01M	-12.16M	-22.53M	-15.23M	-1.74M	-7.6M	-22.62M	57.01M	-108.39M	-353.29M
Capital Expenditures	-208K	-212K	-619K	-422K	-1.49M	-4.28M	-573K	-38K	0	0
CapEx % of Revenue	0.03%	0.05%	0.12%	0.11%	-	-	0.03%	0.02%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-40K	0	0	0	0	0	0	0	15.47M	0
Cash from Financing+	41.67M	49.37M	12.21M	57.07M	65.72M	154.51M	1.39M	42.68M	361.08M	410.91M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	23K	76K	833K	3.02M	1.45M	816K	1.9M	222K	-5.38M	5.67M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.19M	-19.05M	-25.23M	-32.62M	-67.18M	-80.06M	-54.29M	-80.18M	-99.91M	-157.41M
FCF Margin %	-1.84%	-4.12%	-4.85%	-8.39%	-	-	-2.9%	-34.43%	-112.77%	-
FCF Growth %	-0.49%	-0.7%	-0.32%	-0.29%	-1.06%	-0.19%	0.32%	-0.48%	-0.25%	-0.58%
FCF per Share	-24.48	-48.64	-41.70	-39.16	-52.57	-37.50	-20.64	-23.78	-14.49	-3.35
FCF Conversion (FCF/Net Income)	0.97x	0.87x	0.90x	0.73x	0.84x	0.94x	0.82x	0.96x	0.29x	0.76x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.48%	-43.8%	-48.08%	-75.32%	-122.74%	-80.93%	-58.81%	-124.87%	-289.17%	-59.28%
Return on Invested Capital (ROIC)	-279.8%	-149.17%	-78.72%	-82.67%	-132.63%	-120.92%	-76.31%	-135.39%	-2392.09%	-73.87%
Gross Margin	-	-	-	-	-	-	100%	100%	100%	-
Net Margin	-185.62%	-468.84%	-523.27%	-1140.64%	-	-	-351.14%	-3598.75%	-38238.15%	-
Debt / Equity	-	-	-	-	0.08x	0.04x	0.06x	0.09x	-	-
FCF Conversion	0.97x	0.87x	0.90x	0.73x	0.84x	0.94x	0.82x	0.96x	0.29x	0.76x
Revenue Growth	-	-23.94%	12.47%	-25.3%	-100%	-	-	-87.57%	-61.96%	-100%

Revenue by Segment

	2023
License	-
License Growth	-

Frequently Asked Questions

Growth & Financials

Spyre Therapeutics, Inc. (SYRE) saw revenue decline by 100.0% over the past year.

Spyre Therapeutics, Inc. (SYRE) reported a net loss of $149.0M for fiscal year 2024.

Dividend & Returns

Spyre Therapeutics, Inc. (SYRE) has a return on equity (ROE) of -59.3%. Negative ROE indicates the company is unprofitable.

Spyre Therapeutics, Inc. (SYRE) had negative free cash flow of $161.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Spyre Therapeutics, Inc. (SYRE) 10-Year Financial Performance & Capital Metrics

SYRE • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0 -100.0%
EBITDA -$208M +13.8%
Net Income -$208M +38.6%
EPS (Diluted) -3.18 +93.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -59.28% +79.5%
ROIC -73.87% +96.9%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM83.73%

ROCE

10Y Avg-78.09%

5Y Avg-85.99%

3Y Avg-98.82%

Latest-48.26%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	6.08M	4.63M	5.21M	3.89M	0	0	18.74M	2.33M	886K	0
Revenue Growth %	-	-0.24%	0.12%	-0.25%	-1%	-	-	-0.88%	-0.62%	-1%
Cost of Goods Sold+	0	0	0	0	901K	1.62M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	-901K	-1.62M	18.74M	2.33M	886K	0
Gross Margin %	-	-	-	-	-	-	1%	1%	1%	-
Gross Profit Growth %	1%	-	-	-	-	-0.8%	12.54%	-0.88%	-0.62%	-1%
Operating Expenses+	17.4M	26.53M	32.88M	49.35M	79.43M	79.86M	84.39M	87.11M	243.19M	208.57M
OpEx % of Revenue	2.86%	5.73%	6.32%	12.69%	-	-	4.5%	37.4%	274.48%	-
Selling, General & Admin	5.95M	8.39M	10.07M	12.63M	14.83M	20.22M	27.32M	28.53M	39.95M	45.78M
SG&A % of Revenue	0.98%	1.81%	1.93%	3.25%	-	-	1.46%	12.25%	45.09%	-
Research & Development	11.45M	18.14M	22.82M	36.72M	64.6M	59.64M	57.07M	58.58M	89.5M	162.79M
R&D % of Revenue	1.88%	3.92%	4.38%	9.44%	-	-	3.05%	25.15%	101.02%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	113.74M	0
Operating Income+	-11.31M	-21.91M	-27.68M	-45.46M	-80.33M	-81.48M	-65.65M	-84.78M	-242.3M	-208.57M
Operating Margin %	-1.86%	-4.73%	-5.32%	-11.69%	-	-	-3.5%	-36.4%	-273.48%	-
Operating Income Growth %	-0.27%	-0.94%	-0.26%	-0.64%	-0.77%	-0.01%	0.19%	-0.29%	-1.86%	0.14%
EBITDA+	-11.23M	-21.77M	-27.43M	-45.17M	-79.43M	-79.86M	-64.07M	-82.82M	-241.34M	-207.97M
EBITDA Margin %	-1.84%	-4.7%	-5.27%	-11.62%	-	-	-3.42%	-35.56%	-272.39%	-
EBITDA Growth %	-0.26%	-0.94%	-0.26%	-0.65%	-0.76%	-0.01%	0.2%	-0.29%	-1.91%	0.14%
D&A (Non-Cash Add-back)	89K	132K	249K	293K	901K	1.62M	1.58M	1.96M	964K	0
EBIT	-11.31M	-21.91M	-27.68M	-45.46M	-78.25M	-80.89M	-65.65M	-84.78M	-128.56M	-207.97M
Net Interest Income+	22K	244K	482K	1.17M	2.14M	593K	111K	837K	6.15M	21.31M
Interest Income	22K	244K	482K	1.17M	2.14M	593K	111K	837K	6.15M	21.31M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	20K	208K	440K	1.11M	2.08M	588K	-11K	830K	-96.51M	599K
Pretax Income+	-11.29M	-21.7M	-27.24M	-44.35M	-78.25M	-80.89M	-65.66M	-83.95M	-338.82M	-207.97M
Pretax Margin %	-1.86%	-4.69%	-5.23%	-11.41%	-	-	-3.5%	-36.05%	-382.41%	-
Income Tax+	0	0	0	0	0	0	141K	-136K	-26K	51K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-11.29M	-21.7M	-27.24M	-44.35M	-78.25M	-80.89M	-65.8M	-83.81M	-338.79M	-208.02M
Net Margin %	-1.86%	-4.69%	-5.23%	-11.41%	-	-	-3.51%	-35.99%	-382.38%	-
Net Income Growth %	-0.09%	-0.92%	-0.26%	-0.63%	-0.76%	-0.03%	0.19%	-0.27%	-3.04%	0.39%
Net Income (Continuing)	-11.29M	-21.7M	-27.24M	-44.35M	-78.25M	-80.89M	-65.8M	-83.81M	-338.79M	-208.02M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-24.71	-55.40	-45.01	-53.25	-61.23	-37.89	-25.02	-24.86	-46.15	-3.18
EPS Growth %	-0.31%	-1.24%	0.19%	-0.18%	-0.15%	0.38%	0.34%	0.01%	-0.86%	0.93%
EPS (Basic)	-24.71	-55.40	-45.01	-53.25	-61.23	-37.89	-25.02	-24.86	-46.15	-3.18
Diluted Shares Outstanding	457.19K	391.67K	605.13K	832.9K	1.28M	2.13M	2.63M	3.37M	6.9M	47.03M
Basic Shares Outstanding	457.19K	391.67K	605.13K	832.9K	1.28M	2.13M	2.63M	3.37M	6.9M	47.03M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	38.29M	66.42M	54.99M	76.67M	74.5M	149.79M	98.89M	62.26M	341.53M	608.47M
Cash & Short-Term Investments	33.06M	63.5M	50.3M	74.51M	71.95M	146.27M	93.13M	55.71M	339.28M	603.09M
Cash Only	29.29M	47.75M	12.82M	22.46M	19.25M	90.09M	15.14M	34.86M	188.89M	89.42M
Short-Term Investments	3.77M	15.75M	37.48M	52.05M	52.7M	56.18M	77.99M	20.85M	150.38M	513.66M
Accounts Receivable	1.7M	1.22M	3.08M	0	0	0	815K	375K	0	0
Days Sales Outstanding	101.79	95.82	215.84	-	-	-	15.87	58.77	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2.62M	0	0	0	0	0	0	6.17M	2.25M	5.39M
Total Non-Current Assets+	368K	639K	1.09M	1.07M	8.68M	11.83M	11.04M	8.89M	331K	10K
Property, Plant & Equipment	348K	599K	854K	1.02M	7.11M	9.87M	8.36M	6.65M	0	0
Fixed Asset Turnover	17.49x	7.73x	6.09x	3.82x	-	-	2.24x	0.35x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	20K	40K	232K	50K	1.57M	1.96M	2.68M	2.24M	331K	10K
Total Assets+	38.65M	67.06M	56.08M	77.74M	83.18M	161.62M	109.93M	71.14M	341.86M	608.48M
Asset Turnover	0.16x	0.07x	0.09x	0.05x	-	-	0.17x	0.03x	0.00x	-
Asset Growth %	12.19%	0.73%	-0.16%	0.39%	0.07%	0.94%	-0.32%	-0.35%	3.81%	0.78%
Total Current Liabilities+	2.52M	3.96M	5.63M	10.24M	18.36M	16.44M	20.14M	14.66M	31.98M	54.06M
Accounts Payable	176K	168K	389K	663K	3.15M	2.25M	3.32M	677K	896K	666K
Days Payables Outstanding	-	-	-	-	1.28K	506.59	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	71K	20K	0	0	0	1000K	517K	0	0
Other Current Liabilities	621K	1.5M	3.38M	2.78M	3.74M	4.18M	4.99M	4.92M	5.93M	52.79M
Current Ratio	15.17x	16.75x	9.77x	7.49x	4.06x	9.11x	4.91x	4.25x	10.68x	11.26x
Quick Ratio	15.17x	16.75x	9.77x	7.49x	4.06x	9.11x	4.91x	4.25x	10.68x	11.26x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	27K	132K	111K	72K	4.74M	5.34M	5.84M	6.18M	125.86M	36.62M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	4.71M	5.13M	4.62M	4M	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	27K	132K	111K	72K	31K	214K	0	0	125.86M	36.62M
Total Liabilities	2.55M	4.1M	5.74M	10.31M	23.1M	21.79M	25.98M	20.84M	157.84M	90.68M
Total Debt+	0	0	0	0	5.06M	5.45M	5.06M	4.63M	0	0
Net Debt	-29.29M	-47.75M	-12.82M	-22.46M	-14.19M	-84.65M	-10.08M	-30.23M	-188.89M	-89.42M
Debt / Equity	-	-	-	-	0.08x	0.04x	0.06x	0.09x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	36.1M	62.97M	50.34M	67.43M	60.08M	139.83M	83.94M	50.3M	184.02M	517.8M
Equity Growth %	18.29%	0.74%	-0.2%	0.34%	-0.11%	1.33%	-0.4%	-0.4%	2.66%	1.81%
Book Value per Share	78.97	160.76	83.18	80.96	47.01	65.50	31.92	14.92	26.68	11.01
Total Shareholders' Equity	36.1M	62.97M	50.34M	67.43M	60.08M	139.83M	83.94M	50.3M	184.02M	517.8M
Common Stock	0	1K	2K	2K	3K	5K	5K	6K	10K	13K
Retained Earnings	-23.58M	-45.28M	-72.51M	-116.86M	-195.12M	-276.01M	-341.81M	-425.62M	-764.41M	-972.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1K	-4K	-102K	-27K	51K	11K	-20K	-48K	302K	180K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.98M	-18.84M	-24.61M	-32.19M	-65.69M	-75.78M	-53.72M	-80.14M	-99.91M	-157.41M
Operating CF Margin %	-1.8%	-4.07%	-4.73%	-8.28%	-	-	-2.87%	-34.41%	-112.77%	-
Operating CF Growth %	-0.5%	-0.72%	-0.31%	-0.31%	-1.04%	-0.15%	0.29%	-0.49%	-0.25%	-0.58%
Net Income	-11.29M	-21.7M	-27.24M	-44.35M	-78.25M	-80.89M	-65.8M	-83.81M	-338.79M	-208.02M
Depreciation & Amortization	89K	132K	249K	293K	901K	996K	1.58M	1.57M	744K	0
Stock-Based Compensation	767K	0	0	0	0	6.26M	8.04M	7.11M	25.68M	44.83M
Deferred Taxes	0	0	0	0	0	-213K	0	-327K	0	0
Other Non-Cash Items	790K	1.07M	4.77M	1.93M	3.78M	619K	638K	823K	217.67M	10.31M
Working Capital Changes	-1.33M	1.45M	-198K	7.2M	7.1M	-2.54M	1.83M	-5.5M	-5.21M	-4.53M
Change in Receivables	-1.7M	482K	-1.86M	3.08M	0	0	-815K	440K	375K	0
Change in Inventory	0	0	0	0	0	0	0	-440K	0	0
Change in Payables	-169K	-8K	164K	239K	2.58M	-544K	1.06M	-2.64M	218K	-230K
Cash from Investing+	-4.01M	-12.16M	-22.53M	-15.23M	-1.74M	-7.6M	-22.62M	57.01M	-108.39M	-353.29M
Capital Expenditures	-208K	-212K	-619K	-422K	-1.49M	-4.28M	-573K	-38K	0	0
CapEx % of Revenue	0.03%	0.05%	0.12%	0.11%	-	-	0.03%	0.02%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-40K	0	0	0	0	0	0	0	15.47M	0
Cash from Financing+	41.67M	49.37M	12.21M	57.07M	65.72M	154.51M	1.39M	42.68M	361.08M	410.91M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	23K	76K	833K	3.02M	1.45M	816K	1.9M	222K	-5.38M	5.67M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-11.19M	-19.05M	-25.23M	-32.62M	-67.18M	-80.06M	-54.29M	-80.18M	-99.91M	-157.41M
FCF Margin %	-1.84%	-4.12%	-4.85%	-8.39%	-	-	-2.9%	-34.43%	-112.77%	-
FCF Growth %	-0.49%	-0.7%	-0.32%	-0.29%	-1.06%	-0.19%	0.32%	-0.48%	-0.25%	-0.58%
FCF per Share	-24.48	-48.64	-41.70	-39.16	-52.57	-37.50	-20.64	-23.78	-14.49	-3.35
FCF Conversion (FCF/Net Income)	0.97x	0.87x	0.90x	0.73x	0.84x	0.94x	0.82x	0.96x	0.29x	0.76x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-59.48%	-43.8%	-48.08%	-75.32%	-122.74%	-80.93%	-58.81%	-124.87%	-289.17%	-59.28%
Return on Invested Capital (ROIC)	-279.8%	-149.17%	-78.72%	-82.67%	-132.63%	-120.92%	-76.31%	-135.39%	-2392.09%	-73.87%
Gross Margin	-	-	-	-	-	-	100%	100%	100%	-
Net Margin	-185.62%	-468.84%	-523.27%	-1140.64%	-	-	-351.14%	-3598.75%	-38238.15%	-
Debt / Equity	-	-	-	-	0.08x	0.04x	0.06x	0.09x	-	-
FCF Conversion	0.97x	0.87x	0.90x	0.73x	0.84x	0.94x	0.82x	0.96x	0.29x	0.76x
Revenue Growth	-	-23.94%	12.47%	-25.3%	-100%	-	-	-87.57%	-61.96%	-100%

Revenue by Segment

	2023
License	-
License Growth	-

Frequently Asked Questions

Growth & Financials

Spyre Therapeutics, Inc. (SYRE) saw revenue decline by 100.0% over the past year.

Spyre Therapeutics, Inc. (SYRE) reported a net loss of $149.0M for fiscal year 2024.

Dividend & Returns

Spyre Therapeutics, Inc. (SYRE) has a return on equity (ROE) of -59.3%. Negative ROE indicates the company is unprofitable.

Spyre Therapeutics, Inc. (SYRE) had negative free cash flow of $161.9M in fiscal year 2024, likely due to heavy capital investments.